The State of AI in Pharmaceutical Drug Development

This Forbes article was written following a lecture Dr. Niven R. Narain, Ph.D., BERG Co-Founder, President and CEO, gave at Harvard Medical School during the AI Applications Summit for BioPharma in October.

 

The conference provided a useful snapshot into what is happening at the intersection of AI and life sciences and the article describes the author’s ten key observations.

 

To read the full article, click here

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published.